$BIEL ELECTROMAGNETIC PAIN RELIEF/BLOCKING: FEASIBILITY ASSESSMENT https://ntrs.nasa.gov/api/citations/20205008893/downloads/2020ICA_Mullenax_report_24Sep20.pdf https://youtu.be/cGSbtEjJWCk ELECTROMAGNETIC PAIN RELIEF/BLOCKING: FEASIBILITY ASSESSMENT page 15 The treatment method ranked first in this review was pulsed shortwave therapy (PSWT), a low-power RF (MHz range) transmitter operated adjacent to biological tissue at maximum output (saturation) to modulate peripheral nerve activity. ActiPatch is a very small wearable PSWT device that is FDA approved for “adjunctive treatment of musculoskeletal pain” [Anwar-Deen 2020]. It is low cost, low power, and boasts 97% efficacy in reducing pain (85% over a 6-month period) [Staelin 2019]. The device can be secured to the body by physio tape and the area causing pain is bounded by the device’s ring. The device can be turned on and off, and the non-rechargeable battery is capable of 720 hours of operation (one month continuous use). ActiPatch is sold OTC in local pharmacies for ~$30 [ActiPatch 2020]. https://investorshub.advfn.com/uimage/uploads/2022/8/23/rorfrrecoveryrxpostop.jpg https://investorshub.advfn.com/uimage/uploads/2022/3/29/ukvifactipatch.jpg https://investorshub.advfn.com/uimage/uploads/2022/5/9/srbhydonjoybackbrace.jpg https://investorshub.advfn.com/uimage/uploads/2022/10/16/owrlydonjoyknee.jpg